FDA Inspection
The Procter & Gamble Manufacturing CompanyThe Procter & Gamble Manufacturing Company – FDA Inspection, Mar 10, 2017
Record Details
This FDA Inspection record concerns The Procter & Gamble Manufacturing Company, with an inspection on March 10, 2017, issued by the Center for Drug Evaluation and Research, covering drugs.
- People
- Daveta L. Bailey (Company Rep)
- Kara D. Dobbin (Issuing Officer)
View Company Profile
ID · a6223610-6bf6-401c-ba4a-03e9bcfeca7c
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1007310
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
FDA Citations
1- 21 CFR 211.194(a)(8)Second person sign off
Full citation text and observation details available on the Dashboard.
Other FDA inspections of The Procter & Gamble Manufacturing Company
3| Date | Classification | Office | Project area |
|---|---|---|---|
| February 18, 2022 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| August 11, 2011 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| August 20, 2009 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for The Procter & Gamble Manufacturing Company
- FDA Inspection 1162837 - 2022-02-18
- FDA Inspection 740165 - 2011-08-11
- FDA Inspection 609285 - 2009-08-20
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.